Deerfield
Signal active
Investment Firm
Overview
Deerfield is an investment management firm. They provide a healthcare ecosystem through information and investment. They also provide private and public investments across the life science, medical device, diagnostic, digital health, and health service industries.
Highlights
Founded
1994
Industry
Financial Services
Employees
101-250
Investment
272
Lead Investment
143
Exits
128
Stages
Late Stage Venture, Early Stage Venture, Private Equity, Seed
Investor Type
Hedge Fund
Location
New York, New York, United States, North America
Contact Information
Social
Profile Resume
Deerfield, established in 1994 and headquartered in New York, New York, United States, North America., specializes in Late Stage Venture, Early Stage Venture, Private Equity, Seed investments across Biotechnology, Health Care, Pharmaceutical, Life Science, Medical, Genetics, Chemical, Financial Services, Venture Capital, Finance. The organization boasts a portfolio of 271 investments, with an average round size of $88.9M and 128 successful exits. Their recent investments include Arena Pharmaceuticals, PacBio, Sutter Hill Ventures, Mohr Davidow Ventures, Morgan Stanley. The highest investment round they participated in was $1548.8B. Among their most notable exits are Arena Pharmaceuticals and PacBio. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Deerfield has made 272 investments. Their most recent investment was on Jun 05, 2024, when Advanced Medicine Partners raised $32.0M.
Deerfield has made 48 diversity investments. Their most recent diversity investment was on Jul 30, 2024, when Day One Biopharmaceuticals raised $175.0M.
investments
272
Diversity investments
48
Lead investments
143
Number of exits
128
Investments
272
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Feb 13, 2024 | Cogent Biosciences | Biotechnology | 225.0M |
| Feb 21, 2024 | - | - | 110.0M |
| Jun 05, 2024 | Advanced Medicine Partners | Biotechnology | 32.0M |
| Jul 30, 2024 | Day One Biopharmaceuticals | Biotechnology | 175.0M |
Exits
128
Funding Timeline
Funding rounds
272
Investors
1
Funds
3
Funding Rounds
272
Deerfield has raised 272 rounds. Their latest funding was raised on Jul 30, 2024 from a Post-IPO Equity - Day One Biopharmaceuticals round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Feb 13, 2024 | Post-IPO Equity - Cogent Biosciences | - | 225.0M | - |
| Feb 21, 2024 | Series C - MMI | - | 110.0M | - |
| Jun 05, 2024 | Series A - Advanced Medicine Partners | - | 32.0M | - |
| Jul 30, 2024 | Post-IPO Equity - Day One Biopharmaceuticals | - | 175.0M | - |
Investors
1
Deerfield is funded by 1 investor(s). Empire State Development Kantor is the most recent investors.
| Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|
Empire State Development | Yes | Grant - Deerfield | 25.0M |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.